Takeda Pharmaceutical Co Ltd
TSE:4502
Takeda Pharmaceutical Co Ltd
TSE:4502
Price:
4 125 JPY
-0.43%
Updated:
May 2, 2024
EV/FCFF
Enterprise Value to FCFF
Enterprise Value to FCFF
-81
Current
11.5
Median
17.6
Industry
Lower
than median
Lower
than industry value
Enterprise Value to Free Cash Flow To Firm (EV/FCFF) ratio is a valuation multiple that compares the value of a company, debt included, to the amount of free cash flow available for all stakeholders. This metric is very similar to the EV/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
EV/FCFF
=-81
Enterprise Value
/
10.4T
FCFF
-129B
All Countries
| Market Cap | EV/FCFF | ||||
|---|---|---|---|---|---|
| JP |
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
6.5T JPY | -81 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -15 979 072.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
737.4B USD | -238.8 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
3.9T DKK | 55.9 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 13 236.9 | |
| JP |
|
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
|
82T JPY | -3 469.6 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
363.9B USD | 20.2 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
326.1B USD | 38.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
189.7B GBP | 306.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
182.5B CHF | 17.5 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
175.5B CHF | 36.6 |
EV/FCFF Forward Multiples
Forward EV/FCFF multiple is a version of the EV/FCFF ratio that uses forecasted free cash flow to firm for the EV/FCFF calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to firm forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/FCFF
N/A
2-Years Forward
EV/FCFF
N/A
3-Years Forward
EV/FCFF
N/A
You don't have any saved screeners yet
